Emma Aitken1, Andrew Jackson2, Rachel Kearns3, Mark Steven4, John Kinsella3, Marc Clancy2, Alan Macfarlane3. 1. Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, UK. Electronic address: emmaaitken@nhs.net. 2. Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, UK. 3. Department of Anaesthesia, Glasgow Royal Infirmary, Glasgow, UK; Department of Anaesthesia, Critical Care and Pain Medicine, University of Glasgow, Glasgow, UK. 4. Department of Anaesthesia, Golden Jubilee National Hospital, Clydebank, UK.
Abstract
BACKGROUND: Arteriovenous fistulae are the optimum form of vascular access in end-stage renal failure. However, they have a high early failure rate. Regional compared with local anaesthesia results in greater vasodilatation and increases short-term blood flow. This study investigated whether regional compared with local anaesthesia improved medium-term arteriovenous fistula patency. METHODS: This observer-blinded, randomised controlled trial was done at three university hospitals in Glasgow, UK. Adults undergoing primary radiocephalic or brachiocephalic arteriovenous fistula creation were randomly assigned (1:1; in blocks of eight) using a computer-generated allocation system to receive either local anaesthesia (0·5% L-bupivacaine and 1% lidocaine injected subcutaneously) or regional (brachial plexus block [BPB]) anaesthesia (0·5% L-bupivacaine and 1·5% lidocaine with epinephrine). Patients were excluded if they were coagulopathic, had no suitable vessels, or had a previous failed ipsilateral fistula. The primary endpoint was arteriovenous fistula patency at 3 months. We analysed the data on an intention-to-treat basis. This study was registered with ClinicalTrials.gov (NCT01706354) and is complete. FINDINGS:Between Feb 6, 2013, and Dec 4, 2015, 163 patients were assessed for eligibility and 126 patients were randomly assigned to local anaesthesia (n=63) or BPB (n=63). All patients completed follow-up on an intention-to-treat basis. Primary patency at 3 months was higher in the BPB group than the local anaesthesia group (53 [84%] of 63 patients vs 39 [62%] of 63; odds ratio [OR] 3·3 [95% CI 1·4-7·6], p=0·005) and was greater in radiocephalic fistulae (20 [77%] of 26 patients vs 12 [48%] of 25; OR 3·6 [1·4-3·6], p=0·03). There were no significant adverse events related to the procedure. INTERPRETATION: Compared with local anaesthesia, BPB significantly improved 3 month primary patency rates for arteriovenous fistulae. FUNDING: Regional Anaesthesia UK, Darlinda's Charity for Renal Research.
RCT Entities:
BACKGROUND:Arteriovenous fistulae are the optimum form of vascular access in end-stage renal failure. However, they have a high early failure rate. Regional compared with local anaesthesia results in greater vasodilatation and increases short-term blood flow. This study investigated whether regional compared with local anaesthesia improved medium-term arteriovenous fistula patency. METHODS: This observer-blinded, randomised controlled trial was done at three university hospitals in Glasgow, UK. Adults undergoing primary radiocephalic or brachiocephalic arteriovenous fistula creation were randomly assigned (1:1; in blocks of eight) using a computer-generated allocation system to receive either local anaesthesia (0·5% L-bupivacaine and 1% lidocaine injected subcutaneously) or regional (brachial plexus block [BPB]) anaesthesia (0·5% L-bupivacaine and 1·5% lidocaine with epinephrine). Patients were excluded if they were coagulopathic, had no suitable vessels, or had a previous failed ipsilateral fistula. The primary endpoint was arteriovenous fistula patency at 3 months. We analysed the data on an intention-to-treat basis. This study was registered with ClinicalTrials.gov (NCT01706354) and is complete. FINDINGS: Between Feb 6, 2013, and Dec 4, 2015, 163 patients were assessed for eligibility and 126 patients were randomly assigned to local anaesthesia (n=63) or BPB (n=63). All patients completed follow-up on an intention-to-treat basis. Primary patency at 3 months was higher in the BPB group than the local anaesthesia group (53 [84%] of 63 patients vs 39 [62%] of 63; odds ratio [OR] 3·3 [95% CI 1·4-7·6], p=0·005) and was greater in radiocephalic fistulae (20 [77%] of 26 patients vs 12 [48%] of 25; OR 3·6 [1·4-3·6], p=0·03). There were no significant adverse events related to the procedure. INTERPRETATION: Compared with local anaesthesia, BPB significantly improved 3 month primary patency rates for arteriovenous fistulae. FUNDING: Regional Anaesthesia UK, Darlinda's Charity for Renal Research.
Authors: Emma Aitken; Rachel Kearns; Lucian Gaianu; Andrew Jackson; Mark Steven; John Kinsella; Marc Clancy; Alan Macfarlane Journal: J Am Soc Nephrol Date: 2020-07-24 Impact factor: 10.121
Authors: Yong Pey See; Yeoungjee Cho; Elaine M Pascoe; Alan Cass; Ashley Irish; David Voss; Kevan R Polkinghorne; Lai Seong Hooi; Loke-Meng Ong; Peta-Anne Paul-Brent; Peter G Kerr; Trevor A Mori; Carmel M Hawley; David W Johnson; Andrea K Viecelli Journal: Kidney360 Date: 2020-09-14
Authors: Selvakumar Palaniappan; Venkatesh Subbiah; V Raja Gopalan; Poornima Vijaya Kumar; R John Santa Vinothan Journal: Indian J Anaesth Date: 2018-08